Navigation Links
Pro-Dex, Inc. Announces Fiscal Second Quarter And Six-Month Results
Date:1/10/2013

2011Net sales

$   3,007,000

$ 4,017,000Cost of sales

1,974,000

2,770,000Gross profit

1,033,000

1,247,000Operating expenses:Selling expenses

322,000

369,000General and administrative expenses

627,000

688,000Research and development costs

464,000

508,000Total operating expenses

1,413,000

1,565,000Loss from continuing operations before items below

(380,000)

(318,000)Other expense:Interest expense

--

(10,000)Total other expense

--

(10,000)Loss from continuing operations before provision for (benefit from) income taxes

(380,000)

(328,000)Provision for (benefit from) income taxes

(16,000)

1,000Loss from continuing operations

(364,000)

(329,000)Income from discontinued operations, net of provision for income taxes of $21,000 in 2012 and $0 in 2011

16,000

37,000Net loss

$
(348,000)

$ (292,000)Per share data:Loss from continuing operationsBasic

$
(0.11)

$
(0.10)Diluted

$
(0.11)

$
(0.10)Income from discontinued operationsBasic

$
--

$
.01Diluted

$
--

$
.01Net lossBasic

$
(0.11)

$
(0.09)Diluted

$
(0.11)

$
(0.09)Weighted average shares outstanding - basic

3,319,180

3,272,350Weighted average shares outstanding - diluted

3,319,180

3,272,350 

 

PRO-DEX, INC. and SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS For The Six Months Ended December 31,2012

2011Net sales

$   6,468,000

$  9,062,000Cost of sales

4,199,000

5,707,000Gross profit

2,269,000

3,355,000Operating expenses:Selling expenses

'/>"/>
SOURCE Pro-Dex, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Pro-Dex, Inc. Announces Fiscal 2013 First Quarter Results
2. Pro-Dex, Inc. Announces Fiscal 2012 Fourth Quarter And Full-Year Results
3. Pro-Dex, Inc. Announces Fiscal 2012 Fourth Quarter and Full-Year Financial Results Conference Call and Webcast
4. Pro-Dex, Inc. Announces Update Conference Call and Webcast
5. Pro-Dex, Inc. Announces Fiscal Third Quarter and Nine Month Results
6. Pro-Dex, Inc. Announces Fiscal 2012 Third Quarter Financial Results Conference Call and Webcast
7. Pro-Dex, Inc. Appoints Michael J. Berthelot Chief Executive Officer
8. Amgen Announces 31 Percent Increase In 2013 First Quarter Dividend And Increase In Its Share Repurchase Authorization
9. Accelr8 Announces Results of 2012 Annual Meeting
10. OncoSec Medical Announces $7.2 Million Public Offering
11. Isis Announces That ISIS-TTR Rx Was Granted Fast Track Designation For The Treatment Of Patients With FAP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... -- Array BioPharma Inc. (NASDAQ: ARRY ) today ... year of its fiscal year ended June 30, ... Array, noted, "Binimetinib and encorafenib, two innovative oncology ... regulatory submissions in 2016. Additional data shared over ... cancer further validate the value of these programs ...
(Date:8/3/2015)...  Charleston Laboratories, Inc., an emerging specialty pharmaceutical ... program with a Phase 1 study on its ... contains fast-dissolving promethazine and sumatriptan.  This novel migraine ... migraine headache pain and migraine-induced nausea and vomiting ... headaches also suffer from nausea and vomiting," said ...
(Date:8/3/2015)... FLORHAM PARK, N.J. , Aug. 3, 2015 /PRNewswire/ ... primary and secondary endpoints in a phase III study ... in adult patients with chronic non-cancer pain. Naldemedine is ... This is the third Phase III trial in which ... Study results showed that a 0.2 mg tablet ...
Breaking Medicine Technology:Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 2Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 3Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 4Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 5Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 7Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 8Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 9Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 10Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 11Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 12Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charleston's Second Product, CL-H1T 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4
(Date:8/3/2015)... ... ... Illinois Health & Science (IHS) has completed the purchase of IBA Molecular ... IBAM NA’s cyclotron sites and research and development facilities. , “We are ... as a large manufacturing hub in Noblesville, Indiana,” said Ken Smithmier, President and CEO ...
(Date:8/3/2015)... , ... August 03, 2015 , ... ... brokerage firm, announced today that Joe Williams has joined its growing California employee ... delivering HUB's differentiated service model to his clients. Mr. Williams will be joining ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... with accountability for overall performance of the company’s Medicare and Federal Employee Programs ... Cambia’s strategy to deliver better health for members. In this role, Scott is ...
(Date:8/3/2015)... (PRWEB) , ... August 03, ... ... (EMSI), a leading provider of medical information, risk management and investigative services, ... evolution and direction toward focused, expert information solutions that improve business outcomes ...
(Date:8/3/2015)... ... August 03, 2015 , ... Did you know that there ... looking for exceptional and affordable home care options which A-1 Home Care Agency specialize ... few of the credentials A-1 Home Care Agency is known for. ...
Breaking Medicine News(10 mins):Health News:Illinois Health & Science Expands Nuclear Medicine Footprint With Purchase of IBA Molecular North America, Inc. 2Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2Health News:Cambia Health Solutions Names Scott Powers President of Government Programs 2Health News:EMSI Announces New Branding: Powerful Information. Improved Outcomes. 2Health News:A-1 Home Care in Los Angeles and Orange County Honors Exceptional Office Staff 2Health News:A-1 Home Care in Los Angeles and Orange County Honors Exceptional Office Staff 3
... stimulate tumor cell growth , New data, generated ... Research Center, Heidelberg, have characterized a molecular pathway underlying ... as an astrocytoma. The authors therefore suggest that therapeutics ... treating individuals with low-grade atrocytomas. , Analysis of the ...
... ... April 16, 2008, PHILADELPHIA, April 8, 2008 ... their children about,drug use or sex than with a seriously ill parent ... want others,to talk with them about end of life issues. The survey, ...
... Derivative Lawsuit Filed in ... ... 2008 KV Pharmaceutical,Company (NYSE: KVa/KVb), a fully integrated specialty ... generic/non-branded prescription pharmaceutical,products, announced today that it has reached a ...
... with high-dose chemotherapy did not have better survival rates ... randomized controlled trial published online April 8 in the ... SCLC accounts for nearly 13 percent of lung cancer ... SCLC initially respond to chemotherapy, most suffer disease recurrence ...
... levels below current targets in adults with type 2 diabetes ... of the arteries, according to new research supported by the ... Institutes of Health. Hardening of the arteries, also known as ... can lead to heart attack, stroke, and death. , ...
... over $7 million to date in its childhood ... ... In recognition of,national Public Health Week, Anthem Blue Cross, in collaboration ... Index (BMI) training and promotion workshops in Pasadena, San Jose,and Bakersfield, ...
Cached Medicine News:Health News:JCI online early table of contents: April 8, 2008 2Health News:JCI online early table of contents: April 8, 2008 3Health News:JCI online early table of contents: April 8, 2008 4Health News:JCI online early table of contents: April 8, 2008 5Health News:JCI online early table of contents: April 8, 2008 6Health News:JCI online early table of contents: April 8, 2008 7Health News:JCI online early table of contents: April 8, 2008 8Health News:JCI online early table of contents: April 8, 2008 9Health News:National Healthcare Decisions Survey: It's Easier to Talk About Drugs and Sex Than End-of-Life Planning 2Health News:KV Pharmaceutical Company Announces Proposed Settlement in Principle of Derivative Shareholder Litigation 2Health News:KV Pharmaceutical Company Announces Proposed Settlement in Principle of Derivative Shareholder Litigation 3Health News:High-intensity chemotherapy does not improve survival in small cell lung cancer 2Health News:Cholesterol, blood pressure control may reverse atherosclerosis in adults with diabetes 2Health News:Cholesterol, blood pressure control may reverse atherosclerosis in adults with diabetes 3Health News:Cholesterol, blood pressure control may reverse atherosclerosis in adults with diabetes 4Health News:Anthem Blue Cross Tackles Childhood Obesity in California Through Free BMI Workshops for Pediatric and Family Medicine Health Care Providers 2Health News:Anthem Blue Cross Tackles Childhood Obesity in California Through Free BMI Workshops for Pediatric and Family Medicine Health Care Providers 3
For presumptive identification of E. coli serogroup O157:H7 cultured on laboratory media....
A direct qualitative enzyme immunoassay for detection of E.coli Shiga Toxin 1 and 2 in fresh or preserved fecal specimens....
A single tube that performs two rapid tests for E. coli from culture. ColiScreen™ combines both the indole test with the glucuronidase test to increase the specificity....
Inquire...
Medicine Products: